Role of HDAC7 in senescence-associated inflammation

HDAC7 在衰老相关炎症中的作用

基本信息

项目摘要

PROJECT SUMMARY Cellular senescence is a hallmark of the aging process and contributes to chronic disease vulnerability. Although senescence acts acutely as a tumor suppressor mechanism, chronically it also contributes to inflammation in aged tissue through the senescence-associated secretory phenotype (SASP). Hence, removal of senescent cells in vivo improves healthspan and lifespan, although pharmacological “senolytic” approaches tend to have toxic side effects, likely limiting the utility of senolytics as tools to promote healthy aging. As proof-of-concept for an alternative approach, suppression of SASP in vivo reduces chronic liver inflammation and delays onset of hepatocellular carcinoma. Recently, we have shown that SASP is dependent on expulsion of cytosolic chromatin fragments (CCF) from the nucleus into the cytoplasm of senescent cells. We have recently linked mitochondrial dysfunction to CCF production through a retrograde mitonuclear signaling pathway. This pathway is blocked by histone deacetylase inhibitors through an unknown mechanism. Unexpectedly, we recently discovered the histone deacetylase HDAC7 localizes in the nucleus of senescent cells, is required for CCF formation, and is sensitive to mitochondrial status. We hypothesize that HDAC7 is a novel component of mitochondria-nucleus retrograde signaling in senescent cells. This proposal has two Aims, to: 1) Determine the mitonuclear signaling role of HDAC7, 2) Determine the nuclear role of HDAC7 in CCF formation. Elucidation of the mechanism of this signaling pathway is of interest to all biologists but can also identify therapeutic targets for reduction of SASP. This approach can uncover alternatives to senolytic drugs for treatment of age-associated disease and promote healthy aging.
项目摘要 细胞衰老是衰老过程的标志,并导致慢性疾病的脆弱性。 虽然衰老作为一种肿瘤抑制机制急性,慢性它也有助于 通过衰老相关分泌表型(SASP)的衰老组织炎症。因此, 体内衰老细胞的减少可以改善健康和寿命,尽管药理学上的“衰老清除”方法 往往具有毒副作用,可能限制了senolytics作为促进健康衰老的工具的效用。作为 另一种方法的概念验证,体内抑制SASP可减少慢性肝脏炎症 并延迟肝细胞癌的发病。最近,我们已经表明,SASP是依赖于驱逐 细胞质染色质碎片(CCF)从细胞核进入细胞质的衰老细胞。我们有 最近通过逆行线粒体信号传导将线粒体功能障碍与CCF产生联系起来, 通路该途径被组蛋白去乙酰化酶抑制剂通过未知的机制阻断。 出乎意料的是,我们最近发现组蛋白去乙酰化酶HDAC7定位于衰老的细胞核中, 是CCF形成所必需的,并且对线粒体状态敏感。我们假设HDAC7是一种 衰老细胞中的视神经核逆行信号的新组分。该提案有两个 目的:1)确定HDAC7的线粒体信号传导作用,2)确定HDAC7的核作用, CCF形成中的HDAC7。阐明这一信号通路的机制是所有人感兴趣的 生物学家,但也可以确定减少SASP的治疗靶点。这种方法可以揭示 用于治疗与年龄相关的疾病和促进健康老龄化的衰老药物的替代品。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Karl Nathan Miller其他文献

Karl Nathan Miller的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Karl Nathan Miller', 18)}}的其他基金

Mitonuclear signaling pathways in senescence-associated inflammation
衰老相关炎症中的线粒体核信号通路
  • 批准号:
    10683280
  • 财政年份:
    2022
  • 资助金额:
    $ 6.16万
  • 项目类别:
Mitonuclear signaling pathways in senescence-associated inflammation
衰老相关炎症中的线粒体核信号通路
  • 批准号:
    10525640
  • 财政年份:
    2022
  • 资助金额:
    $ 6.16万
  • 项目类别:
Role of HDAC7 in senescence-associated inflammation
HDAC7 在衰老相关炎症中的作用
  • 批准号:
    10241964
  • 财政年份:
    2019
  • 资助金额:
    $ 6.16万
  • 项目类别:
Role of HDAC7 in senescence-associated inflammation
HDAC7 在衰老相关炎症中的作用
  • 批准号:
    10023144
  • 财政年份:
    2019
  • 资助金额:
    $ 6.16万
  • 项目类别:

相似海外基金

Understanding age at first autism health claim and acute health service use in girls and women relative to boys and men
了解女孩和女性相对于男孩和男性的首次自闭症健康声明和紧急医疗服务使用情况
  • 批准号:
    419977
  • 财政年份:
    2020
  • 资助金额:
    $ 6.16万
  • 项目类别:
    Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 6.16万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Proposal of a model plan for a high-activity operating department in an acute care hospital based on long-term PDCA in the age of minimally invasive treatment
微创治疗时代基于长期PDCA的急症医院高活动手术科室模型方案提出
  • 批准号:
    18K04486
  • 财政年份:
    2018
  • 资助金额:
    $ 6.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ISCHAEMIC ACUTE RENAL FAILURE AND AGE: MODULATION BY ANTI-INFLAMMATORY EMBRYONIC STEM CELL-DERIVED MACROPHAGES
缺血性急性肾衰竭和年龄:抗炎胚胎干细胞源性巨噬细胞的调节
  • 批准号:
    G0801235/1
  • 财政年份:
    2009
  • 资助金额:
    $ 6.16万
  • 项目类别:
    Research Grant
AGE-RELATED DIFFERENCES IN ENERGY EXPENDITURE IN RESPONSE TO ACUTE EXERCISE
剧烈运动时的能量消耗与年龄相关的差异
  • 批准号:
    7951393
  • 财政年份:
    2009
  • 资助金额:
    $ 6.16万
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8306217
  • 财政年份:
    2008
  • 资助金额:
    $ 6.16万
  • 项目类别:
Age-related differences in the acute thermoregulatory responses to cold
对寒冷的急性体温调节反应与年龄相关的差异
  • 批准号:
    347633-2008
  • 财政年份:
    2008
  • 资助金额:
    $ 6.16万
  • 项目类别:
    Postgraduate Scholarships - Master's
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    7530462
  • 财政年份:
    2008
  • 资助金额:
    $ 6.16万
  • 项目类别:
Acute and chronic GPCR Medicated Cardioprotection: Roles of receptor Cross-Talk, Cellular signaling, and effects of Age
急性和慢性 GPCR 药物心脏保护:受体串扰的作用、细胞信号传导以及年龄的影响
  • 批准号:
    nhmrc : 428251
  • 财政年份:
    2008
  • 资助金额:
    $ 6.16万
  • 项目类别:
    Career Development Fellowships
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8134266
  • 财政年份:
    2008
  • 资助金额:
    $ 6.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了